inPROBE for HER2
Breast Cancer
Key Facts
About SDS Optic
SDS Optic is a publicly traded Polish medtech company with a mission to address unmet diagnostic needs in oncology and infectious diseases through its proprietary inPROBE fiber-optic biosensor platform. The company has completed a clinical investigation for HER2 detection in breast cancer and maintains a diversified business model combining long-term R&D with near-term service revenue from antibody manufacturing and optical coatings. Its strategy focuses on advancing its core platform through clinical validation, expanding into new biomarkers, and leveraging its state-of-the-art manufacturing and R&D facilities in Poland and the USA.
View full company profileAbout SDS Optic
SDS Optic is a publicly traded Polish medtech company with a mission to address unmet diagnostic needs in oncology and infectious diseases through its proprietary inPROBE fiber-optic biosensor platform. The company has completed a clinical investigation for HER2 detection in breast cancer and maintains a diversified business model combining long-term R&D with near-term service revenue from antibody manufacturing and optical coatings. Its strategy focuses on advancing its core platform through clinical validation, expanding into new biomarkers, and leveraging its state-of-the-art manufacturing and R&D facilities in Poland and the USA.
View full company profileTherapeutic Areas
Other Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Antifibrotic Therapy Program | MeCo Diagnostics | Pre-clinical |
| APA-1000 Breast Thermotherapy System | Medifocus | Phase III |
| Unnamed Breast Cancer Program | Click Therapeutics | Pilot/Phase 2 |
| Lerociclib (Lerocliclib) | Chemogenics BioPharma | Phase 3 |
| AT-017 | Asieris Pharmaceuticals | Not Specified |
| CDK2 inhibitor | Acellera | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| GCT-007 | Global Cancer Technology | Research |
| NDES | Continuity Biosciences | Pre-clinical |
| INP12 | InnoUp | Clinical |
| Dedicated Breast Radiotherapy System | Ehmet Health | Commercial |
| Liposome Program | NanoTech Pharma | Preclinical/Phase 1/2 |